Research on its effectiveness is ongoing
Below are detailed guidelines for billing CPT Code 96372
This electromagnetic-sensitive axis provides a compelling rationale for developing novel therapeutic strategies that specifically target these pathways in advanced PCa and highlights the critical influence of field parameters on metastatic reprogramming, demonstrating how changes in magnetic field exposures modulate EV-mediated and miR-regulatory processes in PCa metastasis
High-Quality, All-Natural Ingredients - Crafted in the USA, these glutathione supplements are all-natural, non-GMO, vegan, and featuring easily ingestible capsules
~ AlphaMD Your liver is one of the hardest-working organs in the body, responsible for filtering toxins, supporting digestion, and maintaining overall metabolic health
The trial did not resume enrollment Preclinical cardiac evidence: Animal models of myocardial infarction demonstrated RGN-352 reduced scar volume, improved cardiac function, and increased survival, forming the basis for the clinical program (PMID: 25015963) RGN-259 (Thymosin Beta-4 Ophthalmic Solution for Dry Eye): ARISE-1 and ARISE-2 Phase 3 trials: Evaluated Thymosin Beta-4 eye drops for dry eye disease with mixed results some endpoints showed improvement in signs of dry eye, but the pre-specified co-primary endpoints were not met, though some secondary endpoints showed statistically significant improvements in certain signs of dry eye (PMID: 23050815) These ophthalmic trials represent the most advanced clinical testing of any Thymosin Beta-4 formulation Independent Pilot Study (China, 2016): A small pilot study randomized 10 STEMI (heart attack) patients into two groups: 5 receiving Thymosin Beta-4-pretreated endothelial progenitor cells (EPCs) and 5 receiving untreated EPCs After 6 months, the Thymosin Beta-4-pretreated group showed trends toward improved cardiac function markers including ejection fraction and exercise capacity, though the very small sample size (n=5 per group) means these results should be considered hypothesis-generating only, not evidence of efficacy (PMID: 27288307) No severe complications were reported in either group during follow-up Important: This study used Thymosin Beta-4 as a cell pretreatment agent ex vivo (EPCs exposed to TB4 before transplantation), not as a directly administered drug
